Home / News Update  / Meril revolutionizes structural heart care with Myval Octapro THV launch at GISE and PCR London Valves 2024

Meril revolutionizes structural heart care with Myval Octapro THV launch at GISE and PCR London Valves 2024

Meril Life Sciences, a leading global med-tech company with its portfolio in cardiovascular and structural heart solutions, celebrated a remarkable achievement with the launch of its cutting-edge Myval Octapro Transcatheter Heart Valve (THV) at GISE

Meril Life Sciences, a leading global med-tech company with its portfolio in cardiovascular and structural heart solutions, celebrated a remarkable achievement with the launch of its cutting-edge Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024. These prestigious global conferences provided the perfect stage for Meril to reinforce its unwavering commitment to transforming structural heart care.

The launch of the Myval Octapro THV introduces lowframe foreshortening for enhanced operator control and precise deployment, making procedures more predictable and effective. It also offers an extensive size matrix, including conventional, intermediate, and extra-large valve sizes, ensuring optimal bioprosthetic valve sizing tailored to individual patient needs.

The unveiling of the Myval Octapro THV at GISE 2024 and PCR London Valves 2024 marked more than a product launch. It is a testament to Meril’s mission to advance structural heart care through collaboration and innovation. In response, the worldwide healthcare community hailed Meril for their latest innovations.

Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute and Fortis Healthcare Medical council, Delhi, “Congratulations to Meril Life Sciences on the launch of the novel MyvalOctapro. We are proud Meril has been consistently innovating to set fresh benchmarks in Transcatheter structural therapies as well as proving them to be safe and effective through well conducted perspective randomised studies. Octapro THV is next-generation balloon expandable valve minimal foreshortening to enable precise deployment and commisural alignment Furthermore, the nine valve sizes (which includes intermediate sizing and extra-large size) enables accurate and appropriate fit to patient’s anatomy. In fact, approx. 50% of Myval THV series implants are intermediate-sized devices, which gives operators a wider options to all possible annular anatomies”.

At London Valves 2024, Meril presented new data from the LANDMARK trial’s subset analysis, complementing its earlier publication in The Lancet. This detailed analysis, now published in the renowned EuroIntervention journal, further reinforces the safety and efficacy of the Myval THV series compared to the Sapien and Evolut THV series.

Mr. Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, expressed gratitude and optimism by saying, “The positive reception of the Myval Octapro THV at these global platforms underscores our commitment to delivering cutting-edge solutions for severe aortic stenosis. We are proud to collaborate with clinicians worldwide in advancing TAVR technology and improving patient outcomes through innovation.”

The results highlighted comparable composite safety and effectiveness outcomes between Myval and Sapien (24.7% vs. 24.1%), with Myval demonstrating a lower rate of permanent pacemaker implantation (15.0% vs. 17.3%) and superior hemodynamic performance. Similarly, the Myval THV series performed on par with Evolut in composite endpoints (24.7% vs. 30%), while showing advantages in reducing pacemaker implantation rates and moderate/severe valve regurgitation. Effective orifice areas were also comparable between 26 and 29 mm of Myval THV series and Evolut THV series, underscoring its strong performance in key clinical measures.

In the small aortic annulus cohort, Myval outperformed Sapien in hemodynamics and showed fewer clinical events than Evolut, despite Evolut’s superior hemodynamic performance. These findings underscore Myval’s pivotal role in advancing TAVR technology across diverse patient groups.

As the Myval Octapro THV begins its journey of clinical impact, Meril remains steadfast in its commitment to alleviating human suffering and enhancing the quality of life through groundbreaking medical technologies.

medgatetoday@gmail.com

Review overview
NO COMMENTS

POST A COMMENT